AKT1 and metabolic dysfunction-associated steatohepatitis: This study also confirmed that Rg1 reduced the changes in PTEN and p-AKT/AKT ratios in NASH cells and animal models, and confirmed that Rg1 treated NASH through the PTEN/AKT pathway in vivo and in vitro.